News
Welcome to Logical Therapeutics’ newsroom.
-
May 27, 2010
Logical Therapeutics Secures $16.9M Series C Financing Round
Lead Candidate, LT-NS001, Shows Evidence of Improved GI Safety for Arthritis Patients -
April 26, 2010
Logical Therapeutics Initiates Enrollment In In New Gastrointestinal Safety Study in Osteoarthritis Patients -
October 27, 2009
Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study
-
October 20, 2009
Logical Therapeutics to Present Data on LT-NS001 at American College of Gastroenterology Annual Meeting
-
May 11, 2009
Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
-
September 8, 2008
Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of their lead program, LT-NS001.
-
August 19, 2008
Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
-
June 13, 2007
Logical Therapeutics Inc. Raises US $30M Series B to Advance Drug Pipeline Targeting Inflammatory Diseases - Naproxen Pro-drug to enter Phase 2 Clinical Development
-
September 5, 2006
Logical Therapeutics Inc. in-licenses novel anti-inflammatory drug
-
August 10, 2006
Logical Therapeutics Inc. Launches Operations with Seed Capital from PA Early Stage Partners
Contact Us
300 Second Avenue
Waltham, MA 02451
781.290.0900 phone
781.290.0911 fax
info@logicaltx.com